HRMY

38.50

0.92% 0.35

Handel nachbörslich: 38.50

Harmony Biosciences Holdings Inc (HRMY)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HRMY? Forum Prognose

Schlusskurs vom Vortag:

$38.15

Offen:

$38.13

24-Stunden-Volumen:

486.05K

Relative Volume:

0.60

Marktkapitalisierung:

$2.24B

Einnahmen:

$899.11M

Nettoeinkommen (Verlust:

$145.62M

KGV:

15.51

EPS:

2.4829

Netto-Cashflow:

$322.54M

1W Leistung:

+0.94%

1M Leistung:

+9.00%

6M Leistung:

+36.57%

1J Leistung:

+1.69%

1-Tages-Spanne:

$37.48

$38.93

1-Wochen-Bereich:

$37.48

$40.02

52-Wochen-Spanne:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Firmenname

Harmony Biosciences Holdings Inc

Sektor

Healthcare (1033)

Branche

Biotechnology (582)

Telefon

(484) 539-9800

Adresse

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Mitarbeiter

293

Twitter

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HRMY Harmony Biosciences Holdings Inc	38.50	2.22B	899.11M	145.62M	322.54M	2.4829
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-23	Herabstufung	Deutsche Bank	Buy → Hold
2026-02-23	Herabstufung	Truist	Buy → Hold
2026-02-11	Fortgesetzt	UBS	Neutral
2025-07-21	Eingeleitet	Truist	Buy
2025-07-10	Fortgesetzt	Goldman	Neutral
2025-06-02	Fortgesetzt	Oppenheimer	Outperform
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-17	Eingeleitet	H.C. Wainwright	Buy
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-09-10	Eingeleitet	UBS	Buy
2024-06-21	Eingeleitet	Citigroup	Buy
2024-01-02	Herabstufung	BofA Securities	Neutral → Underperform
2023-09-25	Herabstufung	Goldman	Neutral → Sell
2023-09-07	Eingeleitet	Berenberg	Buy
2023-04-20	Eingeleitet	BofA Securities	Neutral
2022-10-14	Hochstufung	Janney	Neutral → Buy
2022-10-14	Hochstufung	Jefferies	Hold → Buy
2022-08-03	Herabstufung	Jefferies	Buy → Hold
2022-07-13	Herabstufung	Goldman	Buy → Neutral
2022-07-07	Eingeleitet	Mizuho	Buy
2022-04-14	Eingeleitet	Cantor Fitzgerald	Overweight
2021-12-01	Eingeleitet	Oppenheimer	Outperform
2021-11-04	Eingeleitet	Raymond James	Outperform
2021-09-23	Eingeleitet	Needham	Buy
2021-03-29	Hochstufung	Goldman	Neutral → Buy
2020-09-14	Eingeleitet	Goldman	Neutral
2020-09-14	Eingeleitet	Jefferies	Buy
2020-09-14	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten

Aug 21, 2026

Virtus Advisers LLC Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 21, 2026

Aug 20, 2026

Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 20, 2026

Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 20, 2026

Stephen M. Mollichella Net Worth (2026) - GuruFocus

Aug 20, 2026

Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 20, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Aug 20, 2026

Aug 17, 2026

Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st

Aug 17, 2026

Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 17, 2026

Aug 16, 2026

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat

Aug 16, 2026

Aug 15, 2026

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - stocktwits.com

Aug 15, 2026

Aug 14, 2026

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline - MarketBeat

Aug 14, 2026

Aug 13, 2026

HRMY: Record WAKIX sales drive CNS pipeline progress, with BP-205 and new pitolisant forms advancing - TradingView

Aug 13, 2026

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail

Aug 13, 2026

Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold - MarketBeat

Aug 13, 2026

Aug 12, 2026

Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance

Aug 12, 2026

Harmony Sets Investor Appearance as CNS Strategy Advances - MyChesCo

Aug 12, 2026

Hennion & Walsh Asset Management Inc. Decreases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 12, 2026

Aug 11, 2026

Harmony Biosciences Holdings (HRMY) Stock Analysis: Exploring an 18% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews

Aug 11, 2026